Advertisement
Research Article| Volume 30, ISSUE 11, P1122-1130, December 01, 1991

Download started.

Ok

β-adrenoceptors and antidepressants: Possible 2-phenylethylamine mediation of chronic phenelzine effects

  • David J. McManus
    Footnotes
    Affiliations
    From the Neurochemical Research Unit and PMHAC Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta, USA
    Search for articles by this author
  • Darrell D. Mousseau
    Footnotes
    Affiliations
    From the Neurochemical Research Unit and PMHAC Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta, USA
    Search for articles by this author
  • Paul R. Paetsch
    Footnotes
    Affiliations
    From the Neurochemical Research Unit and PMHAC Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta, USA
    Search for articles by this author
  • Thomas B. Wishart
    Footnotes
    Affiliations
    From the Neurochemical Research Unit and PMHAC Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta, USA
    Search for articles by this author
  • Andrew J. Greenshaw
    Correspondence
    Address reprint requests to A.J. Greenshaw, Neurochemical Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta T6G 2B7, Canada.
    Footnotes
    Affiliations
    Department of Psychology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    Search for articles by this author
  • Author Footnotes
    1 DJM is the recipient of an AHFMR studentship
    4 The authors wish to thank Dr. G.B. Baker for his comments on aspects of this research, Dr. James Wong for his excellent technical assistance, and Ms. S. Omura for her efficient typing of this manuscript.
    2 PRP is the recipient of a MRC studentship
    3 AJG is a Heritage Medical Scholar.
DOI:https://doi.org/10.1016/0006-3223(91)90182-L
β-adrenoceptors and antidepressants: Possible 2-phenylethylamine mediation of chronic phenelzine effects
Previous ArticleTopography of mobility and complexity parameters of the EEG in Alzheimer's Disease
Next ArticleReduced natural killer cell cytotoxicity in depression but not in schizophrenia
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Effects of chronic administration of antidepressant drugs on β-adrenoceptor function were assessed. Tricyclics (imipramine 30 mg/kg/day, desipramine 5 and 10 mg/kg/day) and monoamine oxidase inhibitors [(±)-tranylcypromine 1 mg/kg/day, phenelzine 5 and 10 mg/kg/day] were administered to Male Sprague-Dawley rats (n = 8), via Alzet 2ML2 osmotic minipumps for 28 days. Pumps were implanted subcutaneously in the interscapular region and replaced after 14 days. On days 21 and 22 motor-suppressant actions of the β-adrenoceptor agonist salbutamol (3 mg/kg intraperitoneally [IP]) were assessed as a measure of β-adrenergic receptor sensitivity. On day 28 the animals were killed and their brains used for measurement of drug levels and monoamine oxidase activity. Liver tissue was used to measure the trace amine 2-phenylethylamine. Each drug induced a decrease in the response to salbutamol. With phenelzine the decreased response to salbutamol was not observed at the lower dose. Differences in monoamine oxidase inhibition following phenelzine did not correspond to differential effects on functional β-adrenergic sensitivity. Levels of 2-phenylethylamine, an endogenous amine that is also a metabolite of phenelzine, were significantly higher in the 10-mg/kg/day phenelzine group. These data suggest that 2-phenylethylamine may be one mediator of the chronic actions of phenelzine on β-adrenoceptors.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Amsterdam J.D.
        • Berwish N.J.
        High dose tranylcypromine therapy for refractory depression.
        Pharmacotherapy. 1989; 22: 21-25
        • Azzaro A.
        • Demarest K.T.
        Inhibitory effects of type A and type B monoamine oxidase inhibitors on synaptosomal accumulation of [3H] dopamine: A reflection of antidepressant potency.
        Biochem Pharmacol. 1982; 31: 2195-2197
        • Baker G.B.
        • Greenshaw A.J.
        Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system.
        Cell Mol Neurobiol. 1989; 9: 1-44
        • Baker G.B.
        • Hiob L.E.
        • Dewhurst W.G.
        Effects of monoamine oxidase inhibitors on release of dopamine and 5-hydroxytryptamine from rat striatum in vitro.
        Cell Mol Biol. 1980; 26: 182-185
        • Baker G.B.
        • LeGatt D.F.
        • Coutts R.T.
        Effects of acute and chronic administration of phenelzine on β-phenylethylamine levels in rat brain.
        in: Proc West Pharmacol Soc. 25. 1982: 417-420
        • Baker G.B.
        • Rao T.S.
        • Coutts R.T.
        Electron-capture gas chromatographic analysis of β-phenylethylamine in tissues and body fluids using pentafluorobenzenesulfonyl chloride for derivatization.
        J Chromatogr Biomed Appl. 1986; 381: 211-218
        • Belanger P.M.
        • Atitse-Gbeasson A.
        Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver.
        Can J Physiol Pharmacol. 1982; 61: 524-529
        • Borsini F.
        • Bendotti C.
        • Thurlby P.
        • Samanin R.
        Evidence that systematically administered salbutamol reduces food intake in rats by acting on central beta-adrenergic sites.
        Life Sci. 1982; 30: 905-911
        • Boyer W.F.
        • Lake C.R.
        Initial severity and diagnosis influence the relationship of tricyclic plasma levels to response: A statistical review.
        J Clin Psychopharmacol. 1987; 7: 67-71
        • Caccia S.
        • Fong M.H.
        Kinetics and distribution of the β-adrenergic agonist salbutamol in rat brain.
        J Pharm Pharmacol. 1983; 36: 200-202
        • Campbell I.C.
        • Colburn R.
        • Walker M.N.
        • Lovenberg W.
        • Murphy D.L.
        Norepinephrine and serotonin metabolism in the rat brain: Effects of chronic phenelzine administration.
        in: Neuro-Psychopharmacology. vol 1. Pergamon, Oxford1978: 629
        • Cohen R.M.
        • Aulakh C.S.
        • Campbell I.C.
        • Murphy D.L.
        Functional subsensitivity of α2-adrenoceptors accompanies reductions in yohimbine binding after clorgyline treatment.
        Eur J Pharmacol. 1982; 81: 145-148
        • Coryell W.
        • Turner R.D.
        • Sherman A.
        Desipramine plasma levels and clinical response: Evidence for a curvilinear relationship.
        J Clin Psychopharmacol. 1987; 7: 138-242
        • Drebit R.
        • Baker G.B.
        • Dewhurst W.G.
        Determination of maprotiline and desmethylmaprotiline in plasma and urine by gas chromatography with nitrogen-phosphorus detection.
        J Chromatogr Biomed Appl. 1988; 432: 334-339
        • Dyck L.E.
        The behavioural effects of phenelzine and phenylethylamine may be due to amine release.
        Brain Res Bull. 1984; 12: 23-28
        • Dyck L.E.
        • Dewar K.M.
        Inhibition of aromatic L-amino acid decarboxylase and tyrosine aminotransferase by the monoamine oxidase inhibitor phenelzine.
        J Neurochem. 1986; 46: 1899-1903
        • Dyck L.E.
        • Durden D.A.
        • Boulton A.A.
        Formation of β-phenylethylamine from the antidepressant, phenylethylhydrazine.
        Biochem Pharmacol. 1985; 34: 1925-1929
        • Frances H.
        • Peuch A.J.
        • Chermat R.
        • Simon P.
        Are psychopharmacological effects of betaadrenergic stimulants central or peripheral?.
        Pharmacol Res Commun. 1979; 11: 273-278
        • Georgotas A.
        • Mann J.
        • Friedman E.
        Platelet monoamine oxidase inhibition as a potential indicator of favorable response to MAOIs in geriatric depression.
        Biol Psychiatry. 1981; 16: 997-1001
        • Georgotas A.
        • McCue R.E.
        • Cooper T.B.
        • Nagachondran N.
        • Friedhoff A.
        Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine.
        Psychiatry Res. 1989; 28: 1-9
        • Greenshaw A.J.
        Osmotic mini-pumps: A convenient program for weight adjusted illing concentrations.
        Brain Res Bull. 1986; 16: 759-761
        • Greenshaw A.J.
        • Nazarali A.J.
        • Rao T.S.
        • Baker G.B.
        • Coutts R.T.
        Chronic tranylcypromine treatment induces functional α2-adrenoceptor down-regulation in rats.
        Eur J Pharmacol. 1988; 154: 67-72
        • Hampson D.R.
        • Baker G.B.
        • Coutts R.T.
        A comparison of the neurochemical properties of the stereoisomers of tranylcypromine in the central nervous system.
        Cell Mol Biol. 1986; 32: 333-341
        • Hendley E.D.
        • Snyder S.H.
        Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy.
        Nature. 1968; 220: 1330-1331
        • Johnson E.W.
        • Wolfe B.B.
        • Molinoff P.B.
        Regulation of subtypes of β-adrenergic receptors in rat brain following treatment of 6-hydroxydopamine.
        J Neurosci. 1989; 9: 2297-2305
        • Lai J.C.K.
        • Leung T.K.C.
        • Guest J.F.
        • Lim L.
        • Davidson A.M.
        The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations.
        Biochem Pharmacol. 1980; 29: 2763-2767
        • LaPierre Y.D.
        Course of clinical response to antidepressants.
        Prog Neuropsychopharmacol Biol Psychiatry. 1985; 9: 503-507
        • Lecrubier Y.
        • Puech A.J.
        • Jouvent R.
        • Simon P.
        • Widlocher D.
        A beta adrenergic stimulant salbutamol vs. clomipramine in depression: A controlled study.
        Br J Psychiatry. 1980; 136: 354-358
        • Maj J.
        • Przegalinski E.
        • Mogilnicka E.
        Hypotheses concerning the mechanism of action of antidepressant drugs.
        Rev Physiol Biochem Pharmacol. 1984; 100: 1-74
        • Martin I.L.
        • Baker G.B.
        A gas-liquid chromatographic method for the estimation of β-phenylethylamine in rat brain tissue.
        Biochem Pharmacol. 1977; 26: 1513-1516
        • McGrath P.J.
        • Cooper T.B.
        • Quitkin F.M.
        • Klein D.F.
        Effects of imipramine and phenelzine on plasma PEA levels.
        Psychiatry Res. 1988; 26: 239
        • McManus D.J.
        • Greenshaw A.J.
        Differential effects of chronic antidepressants on behavioural tests of β-adrenergic and GABAB receptor function.
        Psychopharmacology. 1991; 103: 204-208
        • Minneman K.P.
        • Dibner M.D.
        • Wolfe B.B.
        • Molinoff P.G.
        Beta-1 and beta-2 adrenergic receptors in rat cerebral cortex are independently regulated.
        Science. 1979; 204: 866
        • Mogilnicka E.
        The effects of acute and repeated treatment with salbutamol, a β-adrenoceptor agonist, on clonidine-induced hypoactivity in rats.
        J Neural Transm. 1982; 53: 117-126
        • Mozayani A.
        • Coutts R.T.
        • Danielson T.J.
        • Baker G.B.
        Metabolic acetylation of phenelzine in rats.
        Res Commun Chem Pathol Pharmacol. 1988; 62: 397-406
        • Murphy D.L.
        • Aulakh C.S.
        • Garrick N.A.
        How antidepressants work: Cautionary conclusions based on clinical and laboratory studies of the longer-term consequences of antidepressant drug treatment.
        in: Porter R. Bock G. Clark S. Antidepressants and Receptor Function. Foundation Symposium. Wiley, Chichester, UK1986: 106-125
        • Murphy D.L.
        • Aulakh C.S.
        • Garrick N.A.
        • Sunderland T.
        Monoamine oxidase inhibitors as antidepressants: Implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders.
        in: Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. Raven, New York1987: 545-552
        • Ordway G.A.
        • O'Donnell J.M.
        • Frazer A.
        Effects of clenbuterol on central beta-1 and beta-2 adrenergic receptors of the rat.
        J Pharmacol Exp Ther. 1987; 241: 187-195
        • Perry T.L.
        • Hansen S.
        Sustained drug-induced elevation of brain GABA in the rat.
        J Neurochem. 1973; 21: 1167-1175
        • Post R.M.
        • Uhde T.W.
        • Rubinen D.R.
        • Huggins T.
        Differential time course of antidepressant effects after sleep deprivation, ECT, and carbamazepine: Clinical and theoretical implications.
        Psychiatry Res. 1987; 22: 11-19
        • Przegalinski E.
        • Baran L.
        • Siwanowicz J.
        The effect of chronic treatment with antidepressant drugs on salbutamol-induced hypoactivity in rats.
        Psychopharmacology. 1983; 80: 355-359
        • Przegalinski E.
        • Baran L.
        • Siwanowicz J.
        • Bigajska K.
        Repeated treatment with antidepressant drugs prevents salbutamol-induced hypoactivity in rats.
        Pharmacol Biochem Behav. 1984; 21: 695-698
        • Przegalinski E.
        • Siwanowicz J.
        • Bigajska K.
        • Baran L.
        Chronic treatment with electroconvulsive shock prevents the salbutamol-induced hypoactivity in rats.
        J Pharm Pharmacol. 1984; 36: 626-628
        • Quitkin F.M.
        • Stewart J.W.
        • McGrath P.J.
        • et al.
        Phenelzine versus imipramine in the treatment of probable atypical depression: Defining syndrome boundaries of selective MAOI responders.
        Am J Psychiatry. 1988; 145: 306-311
        • Robinson D.S.
        • Campbell I.C.
        • Walker M.
        • Statham N.J.
        • Lovenberg W.
        • Murphy D.L.
        Effects of chronic monoamine oxidase inhibitor treatment on biogenic amine metabolism in rat brain.
        Neuropharmacology. 1979; 18: 771-776
        • Simon P.
        • Lecrubier Y.
        • Jouvent R.
        • Peuch A.J.
        • Allilaire J.F.
        • Widlocher D.
        Experimental and clinical evidence of the antidepressant effects of a beta-adrenergic stimulant.
        Psychol Med. 1978; 8: 335-338
        • Simon P.
        • Lecrubier Y.
        • Jouvent T.
        • Peuch A.
        • Widlocher D.
        Beta-receptor stimulation in the treatment of depression.
        Adv Biochem Psychopharmacol. 1984; 39: 293-299
        • Spyraki C.
        • Fibiger H.C.
        Functional evidence for subsensitivity of β2 receptors after chronic desipramine treatment.
        Life Sci. 1980; 27: 1863-1867
        • Tuomisto J.
        • Smith D.F.
        Effects of tranylcypromine enantiomers on monoamine uptake and release and imipramine binding.
        J Neural Transm. 1986; 65: 135-145
        • Vetulani J.
        • Stawarz R.J.
        • Dingell J.V.
        • Sulser F.
        A possible common mechanism of action of antidepressant treatments. Reduction in the sensitivity of noradrenergic cyclic AMP generating system in the rat limbic forebrain.
        Naunyn Schmiedebergs Arch Pharmacol. 1976; 293: 109-114
        • Vos P.
        • Davenport P.A.
        • Artymyshyn R.P.
        • Frazer A.
        • Wolfe B.B.
        Selective regulation of beta 2 adrenergic receptors by the chronic administration of the lipophilic beta adrenergic agonist clenbuterol: an autoradiographic study.
        J Pharmacol Exp Ther. 1987; 242: 707-712
        • Wurtman R.J.
        • Axelrod J.
        A sensitive and specific assay for the estimation of monoamine oxidase.
        Biochem Pharmacol. 1963; 12: 1439-1440

      Article info

      Publication history

      Received in revised form: June 10, 1991
      Received: January 21, 1991

      Footnotes

      ☆This research was supported by the Alberta Provincial Mental Health Advisory Council (PMHAC) and by the Alberta Heritage Foundation For Medical Research (AHFMR).

      Identification

      DOI: https://doi.org/10.1016/0006-3223(91)90182-L

      Copyright

      © 1991 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX